Medicines planning
46 results
Applied filters
Biosimilar insulin: a primary care discussion
1 July 2026A discussion about the considerations of implementing biosimilar insulin in primary care.
Biosimilar and key generic medicines – June 2026 update
25 June 2026An update about biosimilar and key generic medicines to support system planning and mobilisation
The licence and supporting evidence for golimumab biosimilar
2 June 2026We highlight evidence for available golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).
SPS Horizon Scanning
18 May 2026Know what medicines are in the pipeline. Understand the strategic and operational challenges for the NHS. Start planning early.
The licence and supporting evidence for denosumab 60mg biosimilars
24 April 2026Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for tocilizumab biosimilar
6 March 2026Two licensed tocilizumab biosimilars are available: Tyenne and Avtozma. Learn about the licensed indications, supporting evidence and key differences.
Preparing to use tocilizumab biosimilar
6 March 2026Two tocilizumab biosimilars are now available. We offer general information and implementation advice.
Exagamglogene autotemcel (Casgevy®)
13 February 2026This document highlights key areas where Chief Pharmacists should focus pharmaceutical expertise prior to implementation of exagamglogene autotemcel.
Marketed CAR-T therapy
13 February 2026This document outlines key areas where Chief Pharmacists should focus pharmaceutical expertise prior to an organisation implementing CAR-T therapy.
Costing clinical trials of ATIMPs using the NIHR iCT
11 February 2026Guidance to support and promote consistent pharmacy costing for commercial clinical trials involving ATIMPs.